KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Restructuring (2018 - 2019)

Arbutus Biopharma's Cash from Restructuring history spans 2 years, with the latest figure at -$66000.0 for Q4 2019.

  • For Q4 2019, Cash from Restructuring changed N/A year-over-year to -$66000.0; the TTM value through Dec 2019 reached -$343000.0, changed N/A, while the annual FY2019 figure was -$983000.0, 173.85% down from the prior year.
  • Cash from Restructuring for Q4 2019 was -$66000.0 at Arbutus Biopharma, up from -$138000.0 in the prior quarter.
  • Across five years, Cash from Restructuring topped out at $1.0 million in Q1 2018 and bottomed at -$139000.0 in Q1 2019.